Intra-Operative Radiation Therapy (IORT) Using the IntraBeam® System - A Registry Protocol
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Number of patients with regionally controlled disease
研究概览
简要总结
This registry trial is designed to track the local control rates and side effects of IORT, which will be implemented for women who are suitable partial breast irradiation (PBI) per the latest American Society of Radiation Oncology (ASTRO) guidelines.
详细描述
Eligible patients will be referred for radiation oncology consultation by the operating surgeon. Patients will be presented with all radiation options and if they choose IORT, they will be offered enrollment onto the registry trial and consented accordingly. The registry will collect treatment data from the operation, radiation and pathology notes post IORT for each patient enrolled. Sources of research material, i.e. resected breast tissue and lymph nodes, will be obtained as part of routine clinical care. No additional tissue will be collected from patients due to enrollment on this registry trial. No additional studies will be performed outside of the routine standard of care.
Post treatment, the registry will collect data based on the standard of care follow up schedule. Follow-up visits will be scheduled 2-3 weeks post-operatively, as per standard of care, to review the final pathology and for the initial toxicity assessment. Patients found to have positive margins and/or lymph node involvement may require further surgery and/or additional external beam radiation. Additional follow-up visits with radiation oncology will be scheduled at 6 months and 1, 2, 3, 4, and 5 years following IORT. Toxicity will be scored using Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Local control will be evaluated using clinical exam and semi-annual to annual mammograms. All such information will be tracked and recorded into the registry database.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female gender
- •cT1-2N0, <3.5cm invasive breast cancer, estrogen-receptor positive or DCIS of breast, Grade 1-2, mammographically detected, < 2.5 cm, estrogen-receptor positive
- •Suitable for breast conserving surgery
- •No contraindication to radiation
- •Mammogram within 6 months of planned procedure
- •Fitness for lumpectomy under general anesthesia
- •Planned to receive IORT
- •Exclusion criteria
- •Known axillary lymph node positive breast cancer (negative biopsy not required)
- •Multicentric cancer in the same breast as diagnosed by clinical examination, mammography, ultrasound, MRI or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy.
- •Patients known to have BRCA 1/2 (breast cancer 1, breast cancer 2) gene
- •Patients undergoing neoadjuvant chemotherapy
- •Pregnancy
排除标准
- 未提供
结局指标
主要结局
Number of patients with regionally controlled disease
时间窗: 5 years following radiation therapy
How many patients have recurrent nodal disease following intra-operative radiation
Number of patients with grade 2 or higher toxicities
时间窗: 5 years following radiation therapy
How many patients have toxicity as measured by the CTCAE
Number of patients with locally controlled disease
时间窗: 5 years following radiation therapy
How many patients have recurrent disease following intra-operative radiation
次要结局
未报告次要终点
